Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, single-dose study investigating the
safety and efficacy of NA-1 in patients with subarachnoid hemorrhage (SAH) undergoing
endovascular repair of ruptured intracranial aneurysms. Up to 300 male and female patients
with SAH undergoing endovascular repair of a ruptured intracranial aneurysm will be dosed
with 2.60 mg/kg of NA-1 or placebo as a 10 minute intravenous infusion after completion of
the endovascular procedure on Day 1 of the study period. Subjects will undergo interim
procedures at Day 2-4, Day 30-45, and end-of-study procedures on Day 90.